DALLAS, March 18, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc. (Nasdaq:AVII). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/AVII
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
AVI BioPharma Inc. (AVII) is a biopharmaceutical company specializing in the discovery and development of ribonucleic acid (RNA)-based drugs targeting a range of diseases. The Company has developed and optimized derivatives of its antisense chemistry (phosphorodiamidate morpholino oligomers (PMOs)) that can be designed to target disease mechanisms through mechanisms of action.
Message Board Search for AVII: http://www.boardcentral.com/boards/AVII
In the report, the analyst notes:
"Revenues for the fourth quarter of 2009 were $5.1 million, compared to $5.5 million in the fourth quarter of 2008. Revenues for the full year ended December 31, 2009, were $17.6 million, compared to $21.3 million in the full year ended December 31, 2008, reflecting decreases in research contract revenues of $3.7 million.
"AVII recently announced that CureDuchenne and the Foundation to Eradicate Duchenne (FED) each awarded grants of $250,000 to AVII to support continued research and development of the Company's exon skipping drug candidates for the treatment of Duchenne Muscular Dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. CureDuchenne and FED are U.S. not-for-profit foundations fully dedicated to supporting the research and development of a cure for DMD."
To read the entire report visit: http://www.beaconequity.com/i/AVII
See what investors are saying about AVII at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.